Ozempic is approved to help control blood sugar levels and reduce the risk of heart disease for folks with type 2 diabetes
Tirzepatide's GIPR agonism in fat cells increases cAMP-driven lipolysis, reduces fatty acid re-esterification, and promotes adipocyte differentiation toward a smaller, more metabolically favorable phenotype [7]
Bogman, K., Zysset, Y., Degen, L., Hopfgartner, G., Gutmann, H., Alsenz, J
Longer treatment with GIP receptor antagonists could also reduce bone mineral density (100), and hereby increase the risk of fractures
The best-studied fat-dissolving injectable is deoxycholic acid (a different formula, licensed for the chin as Aqualyx or Kybella), and its patient information notes people may need several sessions, typically up to six spaced about a month apart
doi: 10.1111/dom.12651 68 HeinlaKVasarESedmanTVolkeV